Rifaximin treatment for the irritable bowel syndrome with a positive lactulose hydrogen breath test improves symptoms for at least 3 months

Proton Pump Inhibitor Therapy Use Does Not Predispose to Small Intestinal Bacterial Overgrowth

(2012) Shiva K Ratuapli et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

The Efficacy and Safety of Rifaximin for the Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis

(2011) Stacy B Menees et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Rifaximin Therapy for Patients with Irritable Bowel Syndrome without Constipation

(2011) Mark Pimentel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Evaluating a Bacterial Hypothesis in IBS Using a Modification of Koch’s Postulates: Part 1

(2010) Mark Pimentel   AMERICAN JOURNAL OF GASTROENTEROLOGY

Increased Incidence of Small Intestinal Bacterial Overgrowth During Proton Pump Inhibitor Therapy

(2010) Lucio Lombardo et al.   Clinical Gastroenterology and Hepatology

Abnormal Breath Testing in IBS: A Meta-Analysis

(2010) Eric D. Shah et al.   DIGESTIVE DISEASES AND SCIENCES

Combined oro-caecal scintigraphy and lactulose hydrogen breath testing demonstrate that breath testing detects oro-caecal transit, not small intestinal bacterial overgrowth in patients with IBS

(2010) D. Yu et al.   GUT

Small Intestinal Bacterial Overgrowth in Irritable Bowel Syndrome: Systematic Review and Meta-analysis

(2009) Alexander C. Ford et al.   Clinical Gastroenterology and Hepatology

Bacterial Overgrowth and Irritable Bowel Syndrome: Unifying Hypothesis or a Spurious Consequence of Proton Pump Inhibitors?

(2008) Brennan M.R. Spiegel et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY